ADoBind MC001 / Medicovestor - LARVOL DELTA

ADoBind MC001: A first-in-class tetravalent chemoimmunotherapy ADC targeting folate receptor alpha for treatment of pancreatic cancer (SITC 2025) - "Our data provides preclinical support for the ADoBind platform and justifies advancing MC001 to further development for pancreatic cancer treatment. MC001 is currently in IND-enabling stage of development.Ethics Approval All animal experiments were carried out under the Sanyou Biopharmaceuticals Laboratory Animal Ethics Committee.Abstract 996 Figure 1Request permissionsStructure of MC001Abstract 996 Figure 2Request permissionsSingle-dose in vivo studies of MC001 in a mouse model of pancreatic cancer"

IO biomarker • Oncology • Pancreatic Cancer • Solid Tumor • FOLR1

ADoBind MC001: A first-in-class tetravalent chemoimmunotherapy ADC targeting folate receptor alpha for treatment of pancreatic cancer (AACR-NCI-EORTC 2025) - "Our data provides preclinical support for the ADoBind platform and justifies advancing MC001 to further development for pancreatic cancer treatment. MC001 is currently in IND-enabling stage of development."

IO biomarker • Oncology • Pancreatic Cancer • Solid Tumor • FOLR1

FDA Grants Orphan Drug Designation to Medicovestor’s First-in-Class ADC for Pancreatic Cancer (GlobeNewswire) - "Medicovestor, Inc...announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ADoBind MC001, its lead candidate for the treatment of pancreatic cancer....Medicovestor is currently progressing ADoBind MC001 through IND-enabling studies, with a Phase 1 clinical trial expected to begin in early 2026."

New P1 trial • Orphan drug • Pancreatic Cancer